• NurExone posted a Q2 net loss of US$1.68 million, narrowing from US$1.85 million a year earlier.
• R&D expense rose 7.14% to US$0.75 million on higher material purchases and ExoPTEN development activity.
• G&A costs fell 17.7% to US$0.93 million on lower professional services and legal spend, partly offset by share-based compensation.
• Net financial expense eased to US$0.01 million from US$0.02 million on lower FX translation and royalty-liability revaluation adjustments.
• Made Scientific MOU targets initial GMP exosome batches in H1 2027; management reiterated plans toward a potential H1 2027 IND filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310733PRIMZONEFULLFEED9818447) on August 31, 2026, and is solely responsible for the information contained therein.